Literature DB >> 26235817

Malignant cardiac tumors: diagnosis and treatment.

Chiara Lestuzzi1, Antonino De Paoli2, Tanja Baresic3, Gianmaria Miolo4, Angela Buonadonna4.   

Abstract

Primary malignant cardiac tumors are represented by sarcomas and non-Hodgkin lymphomas. They are rare, affect mostly patients in the fourth decade of life and have a severe prognosis. Both the diagnosis and the treatment require a multidisciplinary approach, and the cardiologist plays a central role both in the diagnosis and in the follow-up. The prognosis may be improved by a careful planning of surgery and by the use of multimodality treatment, including complementary chemotherapy and radiation therapy. A strict follow-up must be planned even after apparently complete cure.

Entities:  

Keywords:  cardiac lymphoma; cardiac malignancy; cardiac radiotherapy; cardiac sarcomas; cardiac tumors; chemotherapy; malignant cardiac tumors; non-Hodgkin lymphoma; sarcoma; surgery

Mesh:

Year:  2015        PMID: 26235817     DOI: 10.2217/fca.15.10

Source DB:  PubMed          Journal:  Future Cardiol        ISSN: 1479-6678


  3 in total

Review 1.  Percutaneous intravenous catheter forceps biopsy in right atrial mass: two case reports and literature review.

Authors:  Lei Chang; Chenyi Gong; Haitao Lu; Yihai Liu; Lina Kang; Jianzhou Chen; Lian Wang; Biao Xu
Journal:  BMC Cardiovasc Disord       Date:  2022-02-20       Impact factor: 2.298

2.  Immunohistochemical Diagnosis of Primary Cardiac Leiomyosarcoma in a Latin American Patient.

Authors:  Ruben Blachman-Braun; Carlos Manuel Aboitiz-Rivera; Alberto Aranda-Fraustro; Adrián Ransom-Rodríguez; Mario Enrique Baltazares-Lipp; Jorge Manuel Catrip-Torres; Jesús Octavio Martínez-Reding
Journal:  Rare Tumors       Date:  2017-03-28

3.  Emergence, Development, and Future of Cardio-Oncology in China.

Authors:  Ying Liu; Yan-Li Zhang; Ji-Wei Liu; Feng-Qi Fang; Jian-Ming Li; Yun-Long Xia
Journal:  Chin Med J (Engl)       Date:  2018-11-05       Impact factor: 2.628

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.